Literature DB >> 20123499

[Histological features and principles of treating testicle tumors in the elderly subject].

P Camparo1, X Durand, C Avances, S Culine, B Segui, J Rigaud.   

Abstract

After the 6th decade, primitive lymphomas are the most frequent tumors of the testis (>30%). They are usually high grade lymphomas that commonly disseminate to the central nervous system. Chemotherapy depends on histological subtype. Germ cell tumors, mainly seminomas, represent less than 20% cases. Therapy do not differ from young adults germ cell tumors. Sex cord stromal tumors, mesenchymal benign tumors, sarcomas and metastasis represent approximately 10% of cases each. The first two are usually cured after orchidectomy. Prognosis of sarcoma is bad. The one of metastasis depends on primitive tumor (prostatic or pulmonary adenocarcinoma or melanoma mainly). Spermatocytic seminoma is a rare and benign tumor, if no sarcomatous component is observed. Mesothelioma are also very rare and of bad prognosis. Other histological subtype are extraordinary rare. This particular histological profile must be in mind when considering the appropriate therapeutic approach of testis tumors in elderly. This work is based on data collected between 1990 to 2005 by the french pathologists of the GELU. (c) 2009 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 20123499     DOI: 10.1016/S1166-7087(09)73361-5

Source DB:  PubMed          Journal:  Prog Urol        ISSN: 1166-7087            Impact factor:   0.915


  2 in total

1.  Malignant melanoma revealed by testicular metastasi.

Authors:  Marie Dusaud; Lucille Adjadj; Alexandre Debelmas; Jean Baptiste Souraud; Xavier Durand
Journal:  Int J Surg Case Rep       Date:  2015-05-21

2.  Ultrasonographic Pattern of Testicular Metastasis of Clear Cell Renal Cell Carcinoma with Pathological Correlation.

Authors:  Florent Libert; Mathieu Cabri-Wiltzer; Emmanuel Dardenne; Anne-Philippe Draguet; Thierry Puttemans
Journal:  J Belg Soc Radiol       Date:  2016-03-31       Impact factor: 1.894

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.